iPSC-γδ NKT Cells (gdNKT Therapy)
Induced pluripotent stem cells (iPSCs) are capable of self-renewing and differentiating into any cell types of the body. iPSCs represent an unlimited starting cell source to generate therapeutic cells of various functions. For cancer treatment, immune cells such as γδ T cells and NK cells are invaluable therapeutic cells due to their ability to express an array of built-in receptors that recognize cancers naturally.
By combining iPSC technology and directed differentiation, CytoMed can generate a novel type of synthetic immune cells, γδ NKT cells, that express cancer recognition receptors of both γδ T cells and NK cells from iPSCs to recognize a wide range of cancers without genetic modification.
Why do we start with iPSCs? (Graphic)
iPSC cells provide an unlimited source material from which to generate therapeutic cells of various functions.
Why do we generate γδ NKT cells? (Graphic)
To integrate more cancer recognition capabilities into one potent, therapeutic product.
How do we generate γδ NKT cells from iPSCs? (Graphic)
From γδ T cell to stem cells and back with more - our synthetic strategy of γδ NKT cells.
Proprietary differentiation protocol
γδ NKT cells
Unique product features of γδ NKT cells (Graphic)
What is the function of γδ NKT cells?
They are potent cancer killers.
γδ NKT cells in action
− γδ NKT cells killing colon cancer cells.
Seek, see and destroy
− unravelling the action of γδ NKT cells frame by frame.